pfizer_building

Pfizer enters $5 billion share buyback deal with Goldman Sachs

pharmafile | March 9, 2016 | News story | Business Services, Research and Development Pfizer, Share buyback, Stock, markets 

US drug major Pfizer (NYSE: PFE) on Wednesday said it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co to repurchase $5 billion of the company’s stock. This agreement is part of Pfizer’s existing share repurchase authorization.

Pfizer will receive about 136 million shares following the transaction on March 10, 2016. At settlement of the agreement, which is expected to occur during the second quarter of 2016, Goldman, Sachs & Co may be required to deliver additional shares of common stock to Pfizer. 

Anjali Shukla

Related Content

anirudh-djo3injpaoe-unsplash_3

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene …

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) …

Pfizer’s Velsipity approved by EC for ulcerative colitis treatment

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) …

Latest content